Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Brivaracetam in the treatment of epilepsy: a review of clinical trial data.

Feyissa AM.

Neuropsychiatr Dis Treat. 2019 Sep 9;15:2587-2600. doi: 10.2147/NDT.S143548. eCollection 2019.

2.

Brivaracetam efficacy and safety in focal epilepsy.

Makke Y, Abou-Khalil B.

Expert Rev Neurother. 2019 Oct;19(10):955-964. doi: 10.1080/14737175.2019.1631160. Epub 2019 Jun 24.

PMID:
31195850
3.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.

Epilepsia. 2016 Apr;57(4):538-48. doi: 10.1111/epi.13340. Epub 2016 Feb 26. Review.

4.

Brivaracetam: a novel antiepileptic drug for focal-onset seizures.

Stephen LJ, Brodie MJ.

Ther Adv Neurol Disord. 2017 Nov 23;11:1756285617742081. doi: 10.1177/1756285617742081. eCollection 2018. Review.

5.

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):47-56. doi: 10.1111/epi.12432. Epub 2013 Oct 28.

6.

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.

Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8.

7.

Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.

Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J.

Epilepsy Res. 2017 Mar;131:70-75. doi: 10.1016/j.eplepsyres.2017.02.007. Epub 2017 Feb 27. Erratum in: Epilepsy Res. 2017 Nov;137:165-166.

8.

Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.

Steinig I, von Podewils F, Möddel G, Bauer S, Klein KM, Paule E, Reif PS, Willems LM, Zöllner JP, Kunz R, Runge U, Kurlemann G, Schubert-Bast S, Rosenow F, Strzelczyk A.

Epilepsia. 2017 Jul;58(7):1208-1216. doi: 10.1111/epi.13768. Epub 2017 May 8.

9.

Brivaracetam add-on therapy for drug-resistant epilepsy.

Bresnahan R, Panebianco M, Marson AG.

Cochrane Database Syst Rev. 2019 Mar 28;3:CD011501. doi: 10.1002/14651858.CD011501.pub2.

PMID:
30920649
10.

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):38-46. doi: 10.1111/epi.12391. Epub 2013 Oct 3.

11.

Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.

Sanon NT, Gagné J, Wolf DC, Aboulamer S, Bosoi CM, Simard A, Messiet E, Desgent S, Carmant L.

Epilepsy Behav. 2018 Feb;79:117-125. doi: 10.1016/j.yebeh.2017.11.019. Epub 2017 Dec 26.

PMID:
29287214
12.

Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.

Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides J.

Epilepsy Res. 2016 Nov;127:179-185. doi: 10.1016/j.eplepsyres.2016.09.003. Epub 2016 Sep 3.

13.

Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis.

Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M.

Neurology. 2016 Apr 5;86(14):1344-1352. doi: 10.1212/WNL.0000000000002545. Epub 2016 Mar 4. Review.

PMID:
26944275
14.

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.

Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E, Gambardella A, De Sarro G, Russo E.

Drug Des Devel Ther. 2015 Oct 19;9:5719-25. doi: 10.2147/DDDT.S81474. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:6509.

15.

Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.

Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H.

Epilepsia. 2016 Feb;57(2):201-9. doi: 10.1111/epi.13267. Epub 2015 Dec 10.

16.

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.

Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P.

Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212. Epub 2015 Oct 16.

17.

Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.

Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M.

Epilepsy Behav. 2019 Oct;99:106505. doi: 10.1016/j.yebeh.2019.106505. Epub 2019 Sep 4.

PMID:
31493736
18.

Emerging drugs for partial-onset epilepsy: a review of brivaracetam.

Gao L, Li S.

Ther Clin Risk Manag. 2016 May 4;12:719-34. doi: 10.2147/TCRM.S90127. eCollection 2016.

19.

First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.

Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, Immisch I, Fuest S, von Podewils F, Kunz R, Hirsch M, Mueller T, Marquetand J, Winter Y, Langenbruch L, Cicanic M, Beyenburg S, Strzelczyk A, Knake S.

BMJ Open. 2019 Nov 4;9(11):e030746. doi: 10.1136/bmjopen-2019-030746.

20.

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.

Ben-Menachem E, Mameniškienė R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K.

Neurology. 2016 Jul 19;87(3):314-23. doi: 10.1212/WNL.0000000000002864. Epub 2016 Jun 22.

Supplemental Content

Support Center